Immunovia
Diagnostics company developing a blood test for early pancreatic cancer detection.
IMMNOV | ST
Overview
Corporate Details
- ISIN(s):
- SE0006091997 (+2 more)
- LEI:
- 549300KHWL6KK1XGUO81
- Country:
- Sweden
- Address:
- Scheelevägen 8, 223 63 LUND
- Website:
- https://immunovia.com/
- Industry:
- Other human health activities
Description
Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-09-30 15:30 |
Immunovia Announces Company On Track with Commercial Test Model Study
|
English | PDF • 289.5 KB | ||
| 2019-09-30 15:30 |
Immunovia meddelar att Commercial Test Model Study fortskrider enligt plan
|
Swedish | PDF • 284.0 KB | ||
| 2019-09-12 15:00 |
Immunovia and world-class teaching hospital finalize agreement for collection o…
|
English | PDF • 295.3 KB | ||
| 2019-09-12 14:58 |
Immunovia och universitetssjukhus i världsklass slutför avtal om insamling av b…
|
Swedish | PDF • 287.6 KB | ||
| 2019-08-23 15:14 | Swedish | PDF • 1.8 MB | |||
| 2019-08-23 15:12 | English | PDF • 1.3 MB | |||
| 2019-07-17 08:00 |
Erlangen University Hospital and Immunovia enter into a collaboration agreement…
|
English | PDF • 564.7 KB | ||
| 2019-07-17 08:00 |
Erlangens universitetssjukhus och Immunovia ingår samarbetsavtal om insamling a…
|
Swedish | PDF • 560.2 KB | ||
| 2019-07-11 15:51 |
Resultat från optimeringsstudien IMMray™ PanCan-d presenteras på PancreasFest 2…
|
Swedish | PDF • 305.8 KB | ||
| 2019-07-11 15:43 |
Results on the IMMray™ PanCan-d optimization study to be presented at PancreasF…
|
English | PDF • 306.2 KB | ||
| 2019-06-19 16:43 |
Immunovias VD Mats Grahn säljer 48 000 Immunovia-aktier till en svensk institut…
|
Swedish | PDF • 292.6 KB | ||
| 2019-06-19 16:40 |
Immunovia's CEO Mats Grahn sells 48,000 Immunovia shares to a Swedish instituti…
|
English | PDF • 293.5 KB | ||
| 2019-06-03 15:00 |
Immunovia announces excellent results across all symptomatic risk groups from I…
|
English | PDF • 597.8 KB | ||
| 2019-06-03 15:00 |
Immunovia meddelar utmärkta resultat för samtliga symptomatiska riskgrupper frå…
|
Swedish | PDF • 596.5 KB | ||
| 2019-04-29 14:00 |
Immunovia meddelar att optimeringsarbetet fortskrider i tid och enligt plan
|
Swedish | PDF • 588.3 KB |
Automate Your Workflow. Get a real-time feed of all Immunovia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunovia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunovia via our API.
Peer Companies
